Key Highlights
- Rocket Pharmaceuticals received FDA accelerated approval for KRESLADI, a groundbreaking gene therapy targeting severe leukocyte adhesion deficiency-I (LAD-I) in pediatric patients.
- Shares of RCKT surged up to 9% during premarket hours and maintained gains of approximately 6% by market open on Friday.
- This marks the inaugural FDA-approved gene therapy designed specifically for severe LAD-I, a critical and rare immune disorder affecting children.
- Rocket received a Rare Pediatric Disease Priority Review Voucher from the FDA, which the biotech company intends to sell for additional capital.
- The greenlight followed a second submission after the agency initially declined the application in June 2024, requesting supplementary clinical data.
Rocket Pharmaceuticals celebrated a major regulatory victory on Friday as the FDA granted approval for its gene therapy KRESLADI, propelling RCKT shares up to 9% during premarket hours before stabilizing at roughly 6% gains at the opening bell.
Rocket Pharmaceuticals, Inc., RCKT
The regulatory greenlight came through the accelerated approval pathway, which relies on preliminary clinical evidence—in this case, enhanced neutrophil CD18 and CD11a surface expression levels. The therapy’s complete clinical effectiveness will require verification through extended data collection from an active clinical trial and a mandatory post-approval registry.
KRESLADI, scientifically designated as marnetegragene autotemce, represents an autologous hematopoietic stem cell-based gene therapy. The treatment is authorized for children diagnosed with severe LAD-I resulting from biallelic mutations in the ITGB2 gene, specifically for those without access to an HLA-matched sibling donor for traditional stem cell transplantation.
LAD-I stands as an extremely rare genetic immune deficiency disorder. The condition triggers repeated infections and presents substantial mortality risk during early childhood when left untreated. Within the United States, the disease occurs in approximately one per 100,000 to one per 200,000 live births, with severe cases representing about two-thirds of all diagnoses.
KRESLADI now represents the pioneering FDA-approved gene therapy available for this devastating condition.
The path to approval encountered significant challenges. The FDA initially rejected the biologics license application during June 2024, requesting that Rocket provide supplementary data before the review process could advance.
Rocket resubmitted its BLA, which the FDA accepted in October 2024, establishing March 28, 2026 as the prescribed action deadline—a timeline the regulatory body successfully honored.
Priority Review Voucher Provides Additional Financial Benefit
Accompanying the regulatory approval, the FDA awarded Rocket a Rare Pediatric Disease Priority Review Voucher. These highly coveted vouchers typically sell to other pharmaceutical manufacturers for several hundred million dollars and represent a substantial financial windfall beyond the approval’s inherent value.
Rocket announced its intention to explore monetization strategies for the voucher to strengthen its financial position.
“The approval of KRESLADI represents an important milestone for the severe LAD-I community,” said CEO Gaurav Shah.
Scientific Foundation Behind the Therapy
The research underpinning KRESLADI’s development received partial funding from the California Institute for Regenerative Medicine. The therapeutic approach targets the ITGB2 gene, which produces a crucial protein enabling white blood cells to effectively combat infections.
The Cranbury, New Jersey-headquartered biotechnology company has pursued this regulatory milestone for multiple years.
The FDA established March 28, 2026 as the action deadline for the resubmitted biologics license application, and the agency delivered its approval decision precisely on target.
